Follow-up of phase i trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

BMC Nephrology

Volumn 11, Issue 1, 2010, Pages

  Peyser, Alexandra ^a   MacHardy, Nathaniel ^b   Tarapore, Freya ^a   MacHardy, Jacqueline ^b   Powell, Leslie ^b   Gipson, Debbie S ^b   Savin, Virginia ^c   Pan, Cynthia ^d   Kump, Theresa ^d   Vento, Suzanne ^a   Trachtman, Howard ^a  

^a Schneider Children's Hospital of North Shore LIJ Health System ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Children's Hospital of Wisconsin ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ROSIGLITAZONE; TACROLIMUS; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; PENILE SWELLING; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; RENAL REPLACEMENT THERAPY; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; DISEASE COURSE; DRUG EFFECT; INFANT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; MALE; THIAZOLIDINEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77249165246     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-11-2     Document Type: Article

References (21)

1. Changing incidence of glomerular disease in Olmstead County, Minnesota: A 30-year renal biopsy study. S Swaminathan N Leung DJ Lager LJ Melton EJ Bergstralh A Rohlinger FC Fervenza, Clin J Am Soc Nephrol 2006 1 483 487 10.2215/CJN.00710805 17699249
2. Clinical course of 110 children and adolescents with primary focal segmental glomerulosclerosis. MM Abrantes LS Cardoso EM Lima JM Silva JS Diniz EA Bambirra EA Oliveira, Pediatr Nephrol 2006 21 482 9 10.1007/s00467-006-0019-4 16520952
3. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. JJ Rydel SM Korbet RZ Borok MM Schwartz, Am J Kid Dis 1995 25 534 542 10.1016/0272-6386(95)90120-5 7702047
4. Focal segmental glomerulosclerosis in adult African Americans. AA Bakir DS Share PS Levy JA Arruda G Dunea, Clin Nephrol 1996 46 306 311 8953119
5. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. DC Cattran GB Appel LA Hebert LG Hunsicker MA Pohl WE Hoy DR Maxwell CL Kunis, Kidney Int 1999 56 2220 6 10.1046/j.1523-1755.1999.00778.x 10594798
6. Factors influencing the course and response to treatment in primary focal segmental glomerulosclerosis. E Alexopoulos M Stangou A Papagianni A Pantzaki M Papadimitriou, Nephrol Dial Transplant 2000 15 1348 56 10.1093/ndt/15.9.1348 10978390
7. Focal segmental glomerular sclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. MJ Chum SM Korbet MM Schwartz EJ Lewis, J Am Soc Nephrol 2004 15 2169 77 10.1097/01.ASN. 0000135051.62500.97 15284302
8. GN-Progress Study Group. Primary glomerulonephritis: an update on renal survival and determinants of progression. O Moranne L Watier J Rossert B Stengel, QJM 2008 101 215 24 10.1093/qjmed/hcm142 18245806
9. Redefining the role of thiazolidinediones in the management of type 2 diabetes. AH Barnett, Vasc Health Risk Manag 2009 5 141 151 19436665
10. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. E Esposito S Cuzzocrea, Curr Med Chem 2009 16 3152 3167 10.2174/092986709788803024 19689289
11. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT study group. MS Joy DS Gipson M Dike L Powell A Thompson S Vento E Eddy AB Fogo JB Kopp D Cattran H Trachtman, Clin J Am Soc Nephrol 2009 4 39 47 10.2215/CJN.02310508 19073787
12. Phase I trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel therapies for resistant FSGS) study group. MS Joy DS Gipson L Powell J MacHardy JC Jennette S Vento C Pan V Savin E Eddy AB Fogo JB Kopp D Cattran H Trachtman, Am J Kidney Dis 2010 55 50 60 10.1053/j.ajkd.2009.08.019 19932542
13. Genetics of focal segmental glomerulosclerosis. RP Woroniecki JB Kopp, Pediatr Nephrol 2007 22 638 644 10.1007/s00467-007-0445-y 17347836
14. Surrogate end points for clinical trials of kidney disease progression. LA Stevens T Greene AS Levey, Clin J Am Soc Nephrol 2006 1 874 884 10.2215/CJN.00600206 17699300
15. Proteinuria as a surrogate outcome in chronic kidney disease. Proceedings of NKF-FDA conference, Bethesda, MD 2008
16. Long-term follow-up after tight control of blood pressure in type 2 diabetes. RR Holman SK Paul MA Bethel HA Neil DR Matthews, N Engl J Med 2008 359 1565 1576 10.1056/NEJMoa0806359 18784091
17. 10-year follow-up of intensive glucose control in type 2 diabetes. RR Holman SK Paul MA Bethel DR Matthews HA Neil, N Engl J Med 2008 359 1577 89 10.1056/NEJMoa0806470 18784090
18. UKPDS and the legacy effect. J Chalmers ME Cooper, N Engl J Med 2008 359 1618 1620 10.1056/NEJMe0807625 18843126
19. New equations to estimate GFR in children with CKD. GW Schwartz A Munoz MF Schneider RH Mak F Kaskel BA Warady SL Furth, J Am Soc Nephrol 2009 20 629 637 10.1681/ASN.2008030287 19158356
20. A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. M Tidman P Sjostrom I Jones, Nephrol Dial Transplant 2008 23 154 160 10.1093/ndt/gfm661 17911090
21. Glomerular filtration rate measurement and prediction equations. AA Soares TF Eyff RB Campani L Ritter JL Camargo SP Silveiro, Clin Chem Lab Med 2009 47 1023 1032 10.1515/CCLM.2009.263 19728843